ICER report critical of Spark Therapeutics' pricing of Luxturna

16 January 2018
2019_biotech_test_vial_discovery_big

A report from the Institute for Clinical and Economic Review (ICER) has provided a negative cost-effectiveness appraisal of Spark Therapeutics’ (Nasdaq: ONCE) orphan gene therapy Luxturna (voretigene neparvovec).

The novel drug was given the nod late last year, becoming the first US Food and Drug Administration-approved directly administered gene therapy that targets a disease caused by mutations in a specific gene.

Spark has since announced the one-time treatment will carry a list price of $850,000, or $425,000 per eye. The therapy treats a form of blindness that affects up to 2,000 people in the USA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology